A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
- PMID: 24771846
- PMCID: PMC4154497
- DOI: 10.1158/2159-8290.CD-13-0424
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
Abstract
Most melanomas harbor oncogenic BRAF(V600) mutations, which constitutively activate the MAPK pathway. Although MAPK pathway inhibitors show clinical benefit in BRAF(V600)-mutant melanoma, it remains incompletely understood why 10% to 20% of patients fail to respond. Here, we show that RAF inhibitor-sensitive and inhibitor-resistant BRAF(V600)-mutant melanomas display distinct transcriptional profiles. Whereas most drug-sensitive cell lines and patient biopsies showed high expression and activity of the melanocytic lineage transcription factor MITF, intrinsically resistant cell lines and biopsies displayed low MITF expression but higher levels of NF-κB signaling and the receptor tyrosine kinase AXL. In vitro, these MITF-low/NF-κB-high melanomas were resistant to inhibition of RAF and MEK, singly or in combination, and ERK. Moreover, in cell lines, NF-κB activation antagonized MITF expression and induced both resistance marker genes and drug resistance. Thus, distinct cell states characterized by MITF or NF-κB activity may influence intrinsic resistance to MAPK pathway inhibitors in BRAF(V600)-mutant melanoma.
Significance: Although most BRAF(V600)-mutant melanomas are sensitive to RAF and/or MEK inhibitors, a subset fails to respond to such treatment. This study characterizes a transcriptional cell state distinction linked to MITF and NF-κB that may modulate intrinsic sensitivity of melanomas to MAPK pathway inhibitors.
©2014 American Association for Cancer Research.
Conflict of interest statement
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4154497/bin/nihms589946f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4154497/bin/nihms589946f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4154497/bin/nihms589946f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4154497/bin/nihms589946f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4154497/bin/nihms589946f5.gif)
Comment in
-
The UPs and DOWNs of MITF in melanoma resistance.Pigment Cell Melanoma Res. 2015 Mar;28(2):132-3. doi: 10.1111/pcmr.12338. Epub 2014 Dec 23. Pigment Cell Melanoma Res. 2015. PMID: 25476804 No abstract available.
Similar articles
-
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712. Nat Commun. 2014. PMID: 25502142 Free PMC article.
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24. Nature. 2010. PMID: 21107323 Free PMC article.
-
BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5930-E5939. doi: 10.1073/pnas.1705206114. Epub 2017 Jul 6. Proc Natl Acad Sci U S A. 2017. PMID: 28684402 Free PMC article.
-
[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31. Ann Pathol. 2013. PMID: 24331719 Review. French.
-
BRAF as a target for cancer therapy.Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. doi: 10.2174/187152011795347469. Anticancer Agents Med Chem. 2011. PMID: 21426297 Review.
Cited by
-
A Gold Standard-Derived Modular Barcoding Approach to Cancer Transcriptomics.Cancers (Basel). 2024 May 15;16(10):1886. doi: 10.3390/cancers16101886. Cancers (Basel). 2024. PMID: 38791964 Free PMC article.
-
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance.Cancers (Basel). 2024 Apr 19;16(8):1571. doi: 10.3390/cancers16081571. Cancers (Basel). 2024. PMID: 38672652 Free PMC article. Review.
-
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.Front Immunol. 2024 Mar 6;15:1336566. doi: 10.3389/fimmu.2024.1336566. eCollection 2024. Front Immunol. 2024. PMID: 38510242 Free PMC article.
-
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.Cell Death Dis. 2024 Mar 12;15(3):208. doi: 10.1038/s41419-024-06580-2. Cell Death Dis. 2024. PMID: 38472212 Free PMC article.
-
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation.JCI Insight. 2024 Feb 6;9(6):e166611. doi: 10.1172/jci.insight.166611. JCI Insight. 2024. PMID: 38319712 Free PMC article.
References
-
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous